Fate Therapeutics launches Phase 1/2 COMPLETE trial of FT839 dual-CAR T therapy in rheumatoid arthritis

Fate Therapeutics launches Phase 1/2 COMPLETE trial of FT839 dual-CAR T therapy in rheumatoid arthritis.

FT839 preclinical update will outline the COMPLETE Phase 1/2 trial design and early progress in rheumatoid arthritis ahead of the meeting.

Data also link treatment response to improvements in patient-reported quality of life, supporting a broader community-care rollout strategy.

Fate Therapeutics secured four ACR Convergence 2026 poster slots for its off-the-shelf CAR T-cell autoimmune programs.

Updated FT819 clinical results will be presented in November, including dosing without conditioning chemotherapy and progress toward outpatient, same-day discharge use.